Jury awards Centocor $1.7B in patent case against Abbott - Minneapolis / St. Paul Business Journal:

http://npersist.com/doc/xmlschema_full.htm
An Abbott spokesman said the companywill appeal. Pa.-based Centocor, a division of (NYSE:JNJ), makea the blockbuster rheumatoid arthritistreatmeny Remicade, and had sued Abbott over Abbott’ s arthritis drug, Humira. Both are so-called anti-TNv arthritis treatments. Horsham, Pa.-based Centocor said it is the exclusive licensewe ofthe patent, which is co-owned by . Centocoe President Kim Taylor said “the jury recognize our valuableintellectual property, finding our patent both valid and We will continue to assert intellectuaol property rights for our immunology therapies, as they offeer significant advances in treatment for patients with a number of immune mediate d inflammatory diseases.
” Abbott spokesman Scott E. Stoffe said, “We are disappointed in this verdict, and we are confident in the meritas of our case and that we will prevaipon appeal. “The evidence clearly established that Humira was the first ofits fully-human anti-TNF antibody medicine,” Stoffel “JNJ’s anti-TNF antibody Remicade, is partially made from mouswe DNA. JNJ did not launch a fully-humab product until April 2009. In fact, only when Humiraw was nearing its approval in 2002 did JNJ amenrd the patent at issuwe in this litigation to claim that it haddiscoveredc fully-human antibodies in 1994.
JNJ acknowledged at trial that it did not stargt working ona fully-human antibody untio 1997 — two years after Abbott discovered Humira and one year after Abboty filed its patent applications for